AMITIZA should not be prescribed to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment and inform their physician if the diarrhea becomes severe.
In clinical trials, the most common adverse reactions (incidence > 4%) were nausea (29%), diarrhea (12%), headache (11%), abdominal pain (8%), abdominal distention (6%), and flatulence (6%).
For full prescribing information, visit http://www.amitiza.com.
AMITIZA(R) is a registered trademark of Sucampo Pharmaceuticals, Inc.
About Chronic Constipation
Constipation is one of the most common digestive complaints, and is the cause of 2.5 million visits to physicians and 92,000 hospitalizations annually. Constipation is defined as unsatisfactory defecation that is characterized by infrequent stools, difficult stool passage or both. Difficult stool passage includes: straining; hard or lumpy stools; difficulty passing stool; incomplete evacuation; prolonged time to stool; or the need for manual maneuvers to pass stool. Symptoms must persist for at least three consecutive months for the condition to be considered chronic.
Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., an emerging pharmaceutical company based
in Bethesda, Md., focuses on the development and commercialization of drugs
based on prostones, a class of compounds derived from functional fatty
acids that occur naturally in the human body. The therapeutic potential of
prostones was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo
Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded
Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief
executive officer and advisor, international business development. Sucampo
|SOURCE Takeda Pharmaceuticals North America, Inc. and Sucampo|
Copyright©2007 PR Newswire.
All rights reserved